Myelofibrosis
📧 Sign up to get email alerts when something new happens for Myelofibrosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2016-08-12Clinical Trial Update: Ruxolitinib in Combination With Autotransplant [NA]
A clinical trial evaluating ruxolitinib in combination with autotransplant for myelofibrosis has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2016-07-11Clinical Trial Update: A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis [Phase 3]
Phase 3 trial of ruxolitinib in primary myelofibrosis and related post-PV/post-ET myelofibrosis has completed, with results posted in 2016.
-
CLINICAL_TRIALS trial_result · 2016-05-23Clinical Trial Update: HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET [Phase 2]
Phase 2 trial of the HSP90 inhibitor AUY922 in myeloproliferative neoplasms including primary myelofibrosis and MF after PV/ET was terminate…
-
CLINICAL_TRIALS trial_result · 2016-05-02Clinical Trial Update: Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis [Phase 2]
A Phase 2 study evaluated a fludarabine-based conditioning regimen before allogeneic stem cell transplantation in myelofibrosis, with result…
-
CLINICAL_TRIALS withdrawal · 2016-04-20Clinical Trial Update: Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders
A clinical trial (NCT02663648) evaluating a cell cycle regulatory gene study in myeloproliferative neoplasms has been withdrawn by the spons…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-03-21Clinical Trial Update: Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder
This clinical trial update notes termination of NCT00722254, a University of Utah study investigating reversible secondary myelofibrosis or …
-
CLINICAL_TRIALS trial_result · 2016-03-08Clinical Trial Update: Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients [Phase 1]
Phase I study of CWP232291 in patients with acute myeloid leukemia and related myeloid neoplasms has completed.
-
CLINICAL_TRIALS research · 2016-02-29Clinical Trial Update: Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
Update on a clinical trial evaluating umbilical cord blood stem cell transplant for leukemia, lymphoma, and other hematologic conditions. Th…
-
CLINICAL_TRIALS trial_result · 2016-02-10Clinical Trial Update: A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial) [Phase 2]
Phase II study evaluating re-treatment with ruxolitinib in patients with primary myelofibrosis after interruption due to loss of response or…
-
CLINICAL_TRIALS trial_result · 2016-01-14Clinical Trial Update: Allogeneic Stem Cell Transplantation (SCT) After Dose-reduced Conditioning for Myelofibrosis Patients [Phase 2]
Phase 2 clinical trial evaluating allogeneic stem cell transplantation with dose-reduced conditioning in patients with myelofibrosis; the st…
-
CLINICAL_TRIALS trial_result · 2015-11-17Clinical Trial Update: Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF) [Phase 1, Phase 2]
A Phase 1/2 study of KB004 in myelodysplastic syndrome and myelofibrosis, sponsored by Humanigen, Inc., is currently suspended.
-
FDA approval · 2015-10-06FDA Approved: JAKAFI — Supplemental Application (Incyte Corporation)
The FDA approved a supplemental application for Jakafi (ruxolitinib) submitted by Incyte Corporation, resulting in labeling updates.
-
CLINICAL_TRIALS trial_result · 2015-08-19Clinical Trial Update: Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) [Phase 2]
Completed Phase 2 study of AP23573 (ridaforolimus) in patients with relapsed or refractory hematologic malignancies, including leukemia, mye…
-
CLINICAL_TRIALS trial_result · 2015-05-07Clinical Trial Update: Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias [Phase 1]
Phase 1 study of TH-302 (evofosfamide), a hypoxia-activated prodrug, in patients with advanced leukemias has been completed, with evaluation…
-
CLINICAL_TRIALS trial_result · 2015-03-06Clinical Trial Update: LBH589 (Panobinostat) for the Treatment of Myelofibrosis [Phase 1, Phase 2]
Phase 1/Phase 2 clinical trial update for LBH589 (panobinostat) in myelofibrosis with current status not reported.
-
CLINICAL_TRIALS trial_result · 2015-03-03Clinical Trial Update: Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) [Phase 4]
Completed Phase 4 exploratory study of INC424 (nilotinib) in patients with primary myelofibrosis or post-polycythemia vera myelofibrosis or …
-
CLINICAL_TRIALS trial_result · 2015-01-05Clinical Trial Update: Decitabine in Treating Patients With Myelofibrosis [Phase 2]
Phase 2 results from a decitabine trial in myelofibrosis have been posted. The study is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2014-12-23Clinical Trial Update: Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases [Phase 1]
Phase 1 trial update on belinostat plus azacitidine in adults with advanced hematologic cancers. The study has completed enrollment and eval…
-
FDA approval · 2014-12-15FDA Approved: JAKAFI — Supplemental Application (Incyte Corporation)
The FDA announced a supplemental application submission for JAKAFI (ruxolitinib) by Incyte, indicating a potential supplemental approval. Th…
-
CLINICAL_TRIALS trial_result · 2014-12-09Clinical Trial Update: A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM) [Phase 2]
Phase 2 trial evaluating zoledronic acid in patients with myelofibrosis with myeloid metaplasia has completed.
-
CLINICAL_TRIALS research · 2014-11-26Clinical Trial Update: CEP-701 (Lestaurtinib) in Myelofibrosis [Phase 1, Phase 2]
Clinical trial update on CEP-701 (lestaurtinib) in myelofibrosis, with additional conditions essential thrombocythemia and polycythemia vera…
-
CLINICAL_TRIALS trial_result · 2014-09-19Clinical Trial Update: Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis [Phase 2]
A Phase 2 trial investigates an alternative dosing strategy for ruxolitinib in myelofibrosis, with completed results posted in 2014.
-
CLINICAL_TRIALS trial_result · 2014-08-28Clinical Trial Update: Anti-TGF-beta Therapy in Patients With Myelofibrosis [Phase 1]
Phase 1 trial evaluating an anti-TGF-beta therapy in myelofibrosis was terminated; results were posted in 2014.
-
CLINICAL_TRIALS trial_result · 2014-08-22Clinical Trial Update: Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis [Phase 2]
A Phase II trial of bevacizumab in myelofibrosis was terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2014-08-12Clinical Trial Update: Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer [Phase 2]
This Phase 2 trial tested sirolimus, tacrolimus, and antithymocyte globulin for preventing graft-versus-host disease in patients undergoing …